{"count":16,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/cc3e52ae-261e-4862-96a8-b051c747fd25/","filing_uuid":"cc3e52ae-261e-4862-96a8-b051c747fd25","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/cc3e52ae-261e-4862-96a8-b051c747fd25/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-04-18T15:10:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":205133,"url":"https://lda.gov/api/v1/clients/205133/","client_id":1573,"name":"ELI LILLY AND COMPANY FKA LILLY USA, LLC","general_description":"Pharmaceutical Company","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/cc3e52ae-261e-4862-96a8-b051c747fd25/","filing_uuid":"cc3e52ae-261e-4862-96a8-b051c747fd25","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/cc3e52ae-261e-4862-96a8-b051c747fd25/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-04-18T15:10:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":205133,"url":"https://lda.gov/api/v1/clients/205133/","client_id":1573,"name":"ELI LILLY AND COMPANY FKA LILLY USA, LLC","general_description":"Pharmaceutical Company","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/d382efdf-4f13-4d42-a2e9-8e476aa54f45/","filing_uuid":"d382efdf-4f13-4d42-a2e9-8e476aa54f45","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/d382efdf-4f13-4d42-a2e9-8e476aa54f45/print/","filing_document_content_type":"text/html","income":null,"expenses":"220000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Amy Shank","dt_posted":"2026-04-20T12:22:15-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"9901 S. Wilcrest Dr","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Houston","registrant_state":"TX","registrant_zip":"77099","registrant":{"id":401103386,"url":"https://lda.gov/api/v1/registrants/401103386/","house_registrant_id":null,"name":"PROFESSIONAL COMPOUNDING CENTERS OF AMERICA","description":"Membership organization providing resources to independent compounding pharmacies","address_1":"9901 S. Wilcrest Dr","address_2":null,"address_3":null,"address_4":null,"city":"Houston","state":"TX","state_display":"Texas","zip":"77099","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY SHANK","contact_telephone":"+1 202-412-0412","dt_updated":"2026-07-24T14:07:59.280567-04:00"},"client":{"id":198794,"url":"https://lda.gov/api/v1/clients/198794/","client_id":12,"name":"PROFESSIONAL COMPOUNDING CENTERS OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-07-21"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/e43e783b-7f1d-4858-97b6-d753c499d8f6/","filing_uuid":"e43e783b-7f1d-4858-97b6-d753c499d8f6","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/e43e783b-7f1d-4858-97b6-d753c499d8f6/print/","filing_document_content_type":"text/html","income":null,"expenses":"40000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Mark Kinney","dt_posted":"2026-07-14T12:52:56-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1550 Columbus Street","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Sun Prairie","registrant_state":"WI","registrant_zip":"53590","registrant":{"id":313098,"url":"https://lda.gov/api/v1/registrants/313098/","house_registrant_id":39121,"name":"INDEPENDENT PHARMACY COOPERATIVE","description":null,"address_1":"1550 Columbus Street","address_2":null,"address_3":null,"address_4":null,"city":"Sun Prairie","state":"WI","state_display":"Wisconsin","zip":"53590","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MR. MARK KINNEY","contact_telephone":"+1 608-628-7311","dt_updated":"2026-07-14T13:14:46.836994-04:00"},"client":{"id":184073,"url":"https://lda.gov/api/v1/clients/184073/","client_id":12,"name":"INDEPENDENT PHARMACY COOPERATIVE","general_description":"National GPO and drug distribution services for independent pharmacies.","client_government_entity":false,"client_self_select":true,"state":"WI","state_display":"Wisconsin","country":"US","country_display":"United States of America","ppb_state":"WI","ppb_state_display":"Wisconsin","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-07-16"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 \"Prescription Pricing for People Act of 2025 IPC supports S. 882 Patients Before Middlemen Act IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - \"Main Street Pharmacy Access Act\" IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) CMS Plan Year 2027 Medicare Drug Price Negotiation Program list of negotiated drug prices and process for negotiations. IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC is opposed to the HRSA 340B proposed rebate model IPC opposes HR 6509/S. 3794 Safe Drug Act of 2026. IPC opposes HR 5316 the \"Drug Shortage Compounding Patient Access Act of 2025\" IPC supports the Breakup Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927 IPC supports the US Department of Labor proposed rule on PBM transparency [RIN 1210-AB37]","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":21818,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"EUGENE","last_name":"KINNEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65102,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"A.","last_name":"COVELLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/0b40eb79-fb41-4351-982f-6ad1e3f21942/","filing_uuid":"0b40eb79-fb41-4351-982f-6ad1e3f21942","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/0b40eb79-fb41-4351-982f-6ad1e3f21942/print/","filing_document_content_type":"text/html","income":null,"expenses":"220000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Amy Shank","dt_posted":"2026-07-20T14:33:46-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"9901 S. Wilcrest Dr","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Houston","registrant_state":"TX","registrant_zip":"77099","registrant":{"id":401103386,"url":"https://lda.gov/api/v1/registrants/401103386/","house_registrant_id":null,"name":"PROFESSIONAL COMPOUNDING CENTERS OF AMERICA","description":"Membership organization providing resources to independent compounding pharmacies","address_1":"9901 S. Wilcrest Dr","address_2":null,"address_3":null,"address_4":null,"city":"Houston","state":"TX","state_display":"Texas","zip":"77099","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY SHANK","contact_telephone":"+1 202-412-0412","dt_updated":"2026-07-24T14:07:59.280567-04:00"},"client":{"id":198794,"url":"https://lda.gov/api/v1/clients/198794/","client_id":12,"name":"PROFESSIONAL COMPOUNDING CENTERS OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-07-21"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154528,"prefix":null,"prefix_display":null,"first_name":"CLAIRE","nickname":null,"middle_name":null,"last_name":"CASEY","suffix":null,"suffix_display":null},"covered_position":"Intern, Congressman Jim Himes - 9/21 - 12/21; Intern, House Appropriations Committee, Subcommittee on Homeland Security - 1/22 - 5/22; Intern, Senator Richard Blumenthal - 5/22 - 7/22; Intern, Congressman Jamie Raskin - 7/22 - 8/22","new":true}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154528,"prefix":null,"prefix_display":null,"first_name":"CLAIRE","nickname":null,"middle_name":null,"last_name":"CASEY","suffix":null,"suffix_display":null},"covered_position":"Intern, Congressman Jim Himes - 9/21 - 12/21; Intern, House Appropriations Committee, Subcommittee on Homeland Security - 1/22 - 5/22; Intern, Senator Richard Blumenthal - 5/22 - 7/22; Intern, Congressman Jamie Raskin - 7/22 - 8/22","new":true}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154528,"prefix":null,"prefix_display":null,"first_name":"CLAIRE","nickname":null,"middle_name":null,"last_name":"CASEY","suffix":null,"suffix_display":null},"covered_position":"Intern, Congressman Jim Himes - 9/21 - 12/21; Intern, House Appropriations Committee, Subcommittee on Homeland Security - 1/22 - 5/22; Intern, Senator Richard Blumenthal - 5/22 - 7/22; Intern, Congressman Jamie Raskin - 7/22 - 8/22","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/80d72449-e0d9-4f60-913b-6858dbeeeed0/","filing_uuid":"80d72449-e0d9-4f60-913b-6858dbeeeed0","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/80d72449-e0d9-4f60-913b-6858dbeeeed0/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-07-20T15:37:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":205133,"url":"https://lda.gov/api/v1/clients/205133/","client_id":1573,"name":"ELI LILLY AND COMPANY FKA LILLY USA, LLC","general_description":"Pharmaceutical Company","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/80d72449-e0d9-4f60-913b-6858dbeeeed0/","filing_uuid":"80d72449-e0d9-4f60-913b-6858dbeeeed0","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/80d72449-e0d9-4f60-913b-6858dbeeeed0/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-07-20T15:37:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":205133,"url":"https://lda.gov/api/v1/clients/205133/","client_id":1573,"name":"ELI LILLY AND COMPANY FKA LILLY USA, LLC","general_description":"Pharmaceutical Company","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/87460353-a57a-415e-87e1-53040d845fc6/","filing_uuid":"87460353-a57a-415e-87e1-53040d845fc6","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/87460353-a57a-415e-87e1-53040d845fc6/print/","filing_document_content_type":"text/html","income":null,"expenses":"30000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Mark Kinney","dt_posted":"2026-10-08T10:03:41-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1550 Columbus Street","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Sun Prairie","registrant_state":"WI","registrant_zip":"53590","registrant":{"id":313098,"url":"https://lda.gov/api/v1/registrants/313098/","house_registrant_id":39121,"name":"INDEPENDENT PHARMACY COOPERATIVE","description":null,"address_1":"1550 Columbus Street","address_2":null,"address_3":null,"address_4":null,"city":"Sun Prairie","state":"WI","state_display":"Wisconsin","zip":"53590","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MR. MARK KINNEY","contact_telephone":"+1 608-628-7311","dt_updated":"2026-07-14T13:14:46.836994-04:00"},"client":{"id":184073,"url":"https://lda.gov/api/v1/clients/184073/","client_id":12,"name":"INDEPENDENT PHARMACY COOPERATIVE","general_description":"National GPO and drug distribution services for independent pharmacies.","client_government_entity":false,"client_self_select":true,"state":"WI","state_display":"Wisconsin","country":"US","country_display":"United States of America","ppb_state":"WI","ppb_state_display":"Wisconsin","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-07-16"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 \"Prescription Pricing for People Act of 2025 IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - \"Main Street Pharmacy Access Act\" IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC monitors HR 879/S.3794 Safe Drug Act of 2026 IPC is opposed to the HRSA 340B proposed rebate model IPC opposes HR 6509/S. 3794 Safe Drug Act of 2026. IPC opposes HR 5316 the \"Drug Shortage Compounding Patient Access Act of 2025\" IPC supports the Breakup Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927 IPC supports the US Department of Labor proposed rule on PBM transparency [RIN 1210-AB37]","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":21818,"prefix":"mr","prefix_display":"MR.","first_name":"MARK","nickname":null,"middle_name":"EUGENE","last_name":"KINNEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":65102,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":"A.","last_name":"COVELLO","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/db269e05-a07d-43c5-a503-71097a9dbe26/","filing_uuid":"db269e05-a07d-43c5-a503-71097a9dbe26","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/db269e05-a07d-43c5-a503-71097a9dbe26/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"William Minor, Partner","dt_posted":"2026-10-19T13:11:46-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"500 8th Street, NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":76855,"url":"https://lda.gov/api/v1/registrants/76855/","house_registrant_id":32113,"name":"DLA PIPER LLP (US)","description":"Law firm.","address_1":"500 8th Street, NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM MINOR","contact_telephone":"+1 202-799-4312","dt_updated":"2026-07-30T08:35:35.415773-04:00"},"client":{"id":67264,"url":"https://lda.gov/api/v1/clients/67264/","client_id":67264,"name":"NOVARTIS","general_description":"Innovative medicines company.","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-05-01"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Intellectual property protections and enforcement. Biopharmaceutical patent policy.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax reform and tax policy.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Tariffs and biotechnology issues related to Treasury and competition with China. S. 5316, Biotech Investment National Security Act of 2026 (BINSA Act).","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.","foreign_entity_issues":"Novartis International AG, interests are those of the parent company.","lobbyists":[{"lobbyist":{"id":147290,"prefix":null,"prefix_display":null,"first_name":"KARINA","nickname":null,"middle_name":null,"last_name":"LYNCH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149001,"prefix":null,"prefix_display":null,"first_name":"RICHARD","nickname":null,"middle_name":null,"last_name":"BURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142802,"prefix":null,"prefix_display":null,"first_name":"MARGARET","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145585,"prefix":null,"prefix_display":null,"first_name":"RACHEL","nickname":null,"middle_name":null,"last_name":"PORTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/6fe909bc-3b9b-479b-b765-bbbc1b0ed024/","filing_uuid":"6fe909bc-3b9b-479b-b765-bbbc1b0ed024","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/6fe909bc-3b9b-479b-b765-bbbc1b0ed024/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-10-19T22:42:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":205133,"url":"https://lda.gov/api/v1/clients/205133/","client_id":1573,"name":"ELI LILLY AND COMPANY FKA LILLY USA, LLC","general_description":"Pharmaceutical Company","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (PL 119-21).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/6fe909bc-3b9b-479b-b765-bbbc1b0ed024/","filing_uuid":"6fe909bc-3b9b-479b-b765-bbbc1b0ed024","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/6fe909bc-3b9b-479b-b765-bbbc1b0ed024/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Zachary Williams","dt_posted":"2026-10-19T22:42:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"777 6th Street NW","registrant_address_2":"8th Floor","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":400976792,"url":"https://lda.gov/api/v1/registrants/400976792/","house_registrant_id":null,"name":"FORBES-TATE","description":"Government Relations Firm.","address_1":"777 6th Street NW","address_2":"8th Floor","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ZACHARY WILLIAMS","contact_telephone":"+1 202-638-0125","dt_updated":"2026-07-20T16:54:02.529740-04:00"},"client":{"id":205133,"url":"https://lda.gov/api/v1/clients/205133/","client_id":1573,"name":"ELI LILLY AND COMPANY FKA LILLY USA, LLC","general_description":"Pharmaceutical Company","client_government_entity":false,"client_self_select":null,"state":"IN","state_display":"Indiana","country":"US","country_display":"United States of America","ppb_state":"IN","ppb_state_display":"Indiana","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-02-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (PL 119-21).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64326,"prefix":null,"prefix_display":null,"first_name":"DERRICK","nickname":null,"middle_name":"M","last_name":"WHITE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68997,"prefix":null,"prefix_display":null,"first_name":"CYNTHIA","nickname":null,"middle_name":null,"last_name":"BROWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":57902,"prefix":null,"prefix_display":null,"first_name":"ELIZABETH","nickname":null,"middle_name":null,"last_name":"GREER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70162,"prefix":null,"prefix_display":null,"first_name":"KRISTINA","nickname":null,"middle_name":null,"last_name":"DUNKLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138827,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ALEXANDER","last_name":"WILLIAMS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/51b9daea-c905-4765-80af-535f7f41d935/","filing_uuid":"51b9daea-c905-4765-80af-535f7f41d935","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/51b9daea-c905-4765-80af-535f7f41d935/print/","filing_document_content_type":"text/html","income":null,"expenses":"210000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Bill McCarthy","dt_posted":"2026-10-20T10:45:35-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1800 M Street, NW, Suite 800 S","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20036","registrant":{"id":401105458,"url":"https://lda.gov/api/v1/registrants/401105458/","house_registrant_id":null,"name":"FDD ACTION","description":"Issue advocacy on U.S. national security and foreign policy","address_1":"1800 M Street, NW, Suite 800 S","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20036","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"WILLIAM MCCARTHY","contact_telephone":"+1 202-207-0190","dt_updated":"2026-07-17T14:19:22.246604-04:00"},"client":{"id":203727,"url":"https://lda.gov/api/v1/clients/203727/","client_id":12,"name":"FDD ACTION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2019-10-01"},"lobbying_activities":[{"general_issue_code":"BAN","general_issue_code_display":"Banking","description":"H.R. 1800, Solidify Iran Sanctions Act (SISA), all provisions. H.R. 3447, Chip Security Act, all provisions. H.R. 5334, Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, all provisions. H.R. 5853, ECRA Statute of Limitations Extension, all provisions. H.R. 6275, China AI Power Report Act, all provisions. H.R. 6331, Addressing Dangerous Vulnerabilities in Exports and Research to Strategic Adversaries, Regimes, and Industrial Entities of Security Concern (ADVERSARIES) Act, all provisions. H.R. 6875, AI OVERWATCH Act, all provisions. H.R. 7003, BIS Strategic Talent Recruitment to Enhance National Guardrails for Technological Handling (STRENGTH) Act, all provisions. H.R. 7184, Preventing Rogue Equipment for Synthetic Substances (PRESS) Act, all provisions. H.R. 8005, Stop Pills That Kill Act, all provisions. H.R. 8170, Multilateral Alignment of Technology Controls on Hardware (MATCH) Act, all provisions. H.R. 9450, Countering Russian Trafficking Act, all provisions. H.R. 9721, Fiscal Sponsorship Transparency Act of 2026, all provisions. H.R. 9764, Hindering Oppressive Nations from Obtaining Revenue Act, all provisions. H.R. 9772, Foreign Funding Transparency Act, all provisions. H.R. 9982, Polisario Front Terrorist Designation Act of 2026, all provisions. H.R. 10076, Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, all provisions. S. 1259, Manifest Modernization Act, all provisions. S. 1705, Chip Security Act, all provisions. S. 1889, Solidify Iran Sanctions Act (SISA), all provisions. S. 2904, Sanctioning Harborers And Dodgers Of Western (SHADOW) Sanctions Act of 2026, all provisions. S. 4281, Multilateral Alignment of Technology Controls on Hardware (MATCH) Act, all provisions. S. 4456, AI OVERWATCH Act, all provisions. S. 5025, Lindsey O. Graham Sanctioning Russia Act of 2026, all provisions. S. 5083, Fiscal Sponsorship Transparency Act of 2026, all provisions. S. 5252, Blocking Large-scale Adversarial Distillation Efforts Act of 2026, all provisions. S. 5356, Lebanon Sanctions, Stabilization, and Support Act, all provisions. S. 5379, BIS Strategic Talent Recruitment to Enhance National Guardrails for Technological Handling (STRENGTH) Act, all provisions. S. 5380, ECRA Statute of Limitations Extension, all provisions. S. 5381, Addressing Dangerous Vulnerabilities in Exports and Research to Strategic Adversaries, Regimes, and Industrial Entities of Security Concern (ADVERSARIES) Act, all provisions. S. 5382, China AI Power Report Act, all provisions. S. 5551, Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act, all provisions. Issues Related to Anti-Money Laundering and Combating the Financing of Terrorism; Captagon, Fentanyl, and International Narcotics Production and Trafficking; Evaluating Sanctions, Export Controls, and AML Regulations, Regulatory Authorities, and Legislative Authorities; Foreign Boycotts of Israel; Foreign Investment in Latin America; Hamas Smuggling Tunnels, Financial Assets, and Funding Streams; IEEPA Reform; Implementation and Oversight of the Countering Americas Adversaries Through Sanctions Act (CAATSA); Iranian Oil Sanctions Enforcement; Monitoring Emerging Economic Security Risks; Muslim Brotherhood Funding Streams; National Security-Related Foreign Investment Screening Processes for U.S. Allies; Non-Western Payment and Messaging Systems; U.S. Adversaries Illicit Finance Activities; U.S. Adversaries Sanctions Evasion Schemes; U.S. China Sanctions Policy; U.S. Corruption Sanctions Policy; U.S. Counter-Kleptocracy Strategy; U.S. Cuba Sanctions Policy; U.S. Digital Assets Policy; U.S. Economic Statecraft Policy; U.S. Export Control Policy; U.S. Hezbollah Sanctions Policy; U.S. Investment Screening and Security; U.S. Iran Sanctions Policy; U.S. Muslim Brotherhood Sanctions Policy; U.S. North Korea Sanctions Policy; U.S. Russia Oil Waivers and Sanctions Policy; U.S. Sanctions Authorities, Implementation, Enforcement, Resourcing, and Policy; U.S. Terror Finance Policy; and U.S. Turkey Sanctions Policy (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"DEF","general_issue_code_display":"Defense","description":"H.R. 3151, SHIPS for America Act of 2025, all provisions. H.R. 4860, U.S.-Taiwan Defense Innovation Partnership Act, all provisions. H.R. 7873 Taiwan Energy Security and Anti-Embargo Act, all provisions. H.R. 8787, Servicemember Payment Data Privacy and Security Act, all provisions. H.R. 9366, Eastern Frontier Defense Infrastructure Readiness Act, all provisions. H.R. 9451, Seized Assets for Battlefield Equipment and Readiness (SABER) Act, all provisions. H.R. 9880, GPS Modernization Acceleration Act, all provisions. H.R.9550, Strategic Unmanned Systems Partnership Act, all provisions. H.R. 10126, Defense Export Modeling Alignment for National Defense (DEMAND) Act, all provisions. H.R. 10766, To direct the Secretary of Defense to update the Critical Asset List of the Department of Defense to incorporate assets critical to the development, deployment, and operation of the Golden Dome missile defense system, all provisions. H.R. 10796, United States-Israel Defense Technology Cooperation Act, all provisions. S. 1541, SHIPS for America Act of 2025, all provisions. S. 2722, Taiwan Energy Security and Anti-Embargo Act, all provisions. S. 4826, Seized Assets for Battlefield Equipment and Readiness (SABER) Act, all provisions. S. 5175, Fast Tracking European Investment in Ukraines Defense Act, all provisions. S. 5548, Securing National Security Systems from Chinese Optical Transceivers Act, all provisions. S. 5590, Electric Grid Supply Chain Security Act, all provisions S. 5595, Weapons Resupply, Stockpile, and Assurance Act, all provisions. S. 5598, Blocking Foreign Cellular Modules in Defense Systems Act of 2026, all provisions. H.R. 8800, National Defense Authorization Act for Fiscal Year 2027, (issues related to Actions to Evaluate and Invest in Ukrainian Defense Technologies; Additional Support for NATO Air Defense Against UAS; AI Agent Discovery and Security Standards; Air Force Fighter Fleet Recapitalization; Amendment to the Atomic Energy Act of 1954; Amendments to the Anti-Boycott Act of 2018; American Security Robotics Act; American-Hellenic-Israeli Eastern Mediterranean Counterterrorism and Maritime Security Partnership Act; Analysis of Threats Posed by Foreign Adversary Access to Controlled Items Within the US; ARMOR Act; Assessment and Report of Foreign Adversary Influence over Strategic Maritime Chokepoints; Assessment of Antisemitism in the Service Academies; Assessment of DOD Display Chain Supply Chain Vulnerabilities; Assessment of Foreign Adversary-Controlled Digital Platforms; Assessment of Military Medical Supply Chains; Assessment of Resilient Missile Defense Sensing Architectures; Assessment of Russian Involvement in Narcotics and Narcotics Trafficking; Audit and Mitigation of Certain Cellular Modules; Audit of CCP-Linked Participation in DOD Contracts and Supply Chains; Baltic Region Security Concerns; Biological Intellectual Property Protection Act; Biotech Investment National Security Act; Briefing on Supply Chain Exposure; Briefing on the Pilot Program to Analyze and Monitor Certain Supply Chains; Bunker Buster Act; Certification Requirement for Motor Carriers Transporting DOD Freight; Certification That No Contractor of DOD Participates in BDS Movement; Chinese Cellular Modules; Chinese Commercial Space Capabilities; Chinese Robotics Capabilities and Strategy; Chinese Supply Chain Monopoly Identification and Diversification; Civilian Cybersecurity Reserve Corps Pilot Program; Clarification of Authority to Counter UAS for Members of the National Guard; Classification of Pass-Through Funding Within Defense Budget Materials; CLEAR Path Act; Codification of EOs Relating to American Airspace Sovereignty and Drone Dominance; Commercial Software for Contested Logistics; Countering Adversarial Gray Zone Campaigns; Countering Biotechnology Threats from Foreign Adversaries; Countering Cartel Hydrocarbon Smuggling; Countering Iranian Threat Networks in the Eastern Mediterranean; Criminal Penalties for Providing Material Support to a Covered Foreign Country; Critical Minerals Traceability Pilot Program; Cyber Incident Reporting Requirements for Operationally Critical Contractors; Deter PRC Aggression Against Taiwan Act; Determination on Eligibility for Cyber Pilot Program; DETERRENCE Act; DETERRENT Act; Development, Test, Evaluation, Demonstration, and Transition to Production of Alternative Low-Cost Weapon Systems; Dialogue and Measures with Respect to Moldova; DIB and Acquisition Reform; Disclosure of Foreign Funding for Elementary and Secondary Schools; DOD Economic Defense Unit; DOD Grant Program to Improve Cybersecurity Resilience of Department-Owned Joint-Use Airports; DOD Procurement Reform; Domestic and Covered Allied or Partner Country Critical Transportation Manufacturing Assessment; Domestic Production of Short-Wave Infrared Quantum Dot Materials; Electromagnetic Spectrum Operations Review; Elimination of Use of Certain Payment Processing Equipment, Systems, or Services; End the Cyprus Embargo Act; Ensuring Mature-node Semiconductor Availability; Establishment of Army Information Operations Center of Excellence; Establishment of China Watcher Program; Establishment of DIU Office in Israel; Establishment of Eastern Flank NATO Regional SOC and CSIRT Program; Establishment of Strategic Airports Cybersecurity Infrastructure Program; Establishment of US-Israel AI Center; Establishment of US-Ukraine Critical Minerals Investment Screening Mechanism; Evaluation of Standards for EMP Protection; Exceptions for Notifications to the US Government Relating to Specified Foreign Entities; Expanding the Defense Industrial Base Sales Act; Expansion of Permissible Uses of Ukraine Support Fund; Extension and Modification of Indo-Pacific Maritime Security Initiative; Extension and Modification of Report on Military and Security Developments Involving the PRC; Extension of Limitation on Availability of Funds for the Iraqi Security Forces; Extension of Report on IRGC-Affiliated Operatives Abroad; FASC Exclusion Orders for Chinese Military Company Designees; Feasibility of Permanent Basing an F-35 Squadron in Poland; Feasibility Study on Combatant Command Critical Minerals Management; Feasibility Study on Tactical Information Operations Command Authority; GAO Report on AI Integration Across Defense Operations; Government-Wide Critical Mineral Procurement and Resale Authorities Feasibility Study; GPS Modernization; GUARD Act; Guard the Skies Act; Hardware and Firmware Assurance Pilot Program; IMF Reform; Increased Maximum Production Capacity Plans for Key Munitions and Weapons Systems; Indo-Pacific Trilateral Production Pilot Program; Integrated Air and Missile Defense Architecture; Integration of Demand for FMS into Industrial Base Planning; Internal Base Hardening Assessments and Logistics-Node Threat Mitigation; Joint DOD-DHS Security Pilot Program on Prevention of Terrorist Threats Involving Motor Vehicles; Joint US-Taiwan Research, Development, Test, and Evaluation Program; Limitation on Provision of Funds to Elementary and Secondary Schools Hosting Confucius Institutes and Classrooms; Long Range Anti-Ship Missile Surface and Ground Launch; Maritime Security Measures; Medical Supply Chain Risk Identification and Transparency Enhancement; Military Treatment Facility Readiness, Network Reliance, and Cyber Resilience; Modification of Report on Military and Security Developments Involving Russia; Modification of Report on the Military Power of Iran; Modification to Disclosure Requirements for US-Based Foreign Media Outlets; Modifications to Congressional Review of Sanctions with Respect to Russia; Modifications to Public Reporting of Chinese Military Companies Operating in the US; Modifications to Strategy to Eliminate Sourcing of Computer Displays from Certain Nations; Modifications to the Port Security Grant Program; Moldovas Airspace Awareness and Defense Capabilities; MTS Cyber Act; Multiyear Procurement Authorities; National Security Commission on Robotics; NSA Support for DIB and Critical Infrastructure Cybersecurity Operations; Oversight of Military-to-Military Exchanges and Contacts Between the US and Russia; PAID OFF Act; Participation of Ukrainian Students in US Service Academies; Phased Inventory Benchmarks for Combat Coded Fighter Aircraft; Photovoltaic Modules from Foreign Entities of Concern; PILLAR Act; Pilot Program for Adaptive Electronic Warfare-Resilient and Quantum-Secure Autonomy Small UAS Architecture Testing; Pilot Program on DOD Partnerships with IHE Recognized in the NCAE-C Program for Cyber Research; Pilot Program on National Security Risk Identification and Review for Adversarial Capital; Pilot Program on Semiconductor Antitampering and Authenticity Validation; Pilot Program to Improve Participation by Small Business Concerns in Certain DOD Contracts; Plan on Remediation of Certain Equipment and Computational Facilities Owned or Controlled by a Foreign Adversary; Plan Required for Full Participation by Taiwan in the RIMPAC; Plan to Counter PRC Influence and Activities in the FAS; Potential Designation of Information as a Domain of Warfare; PRC Militarization and Surveillance Activities; Procurement of Amoxicillin; Prohibition Against US Recognition of Russia's Claim of Sovereignty over Any Portion of Ukraine; Prohibition on DOD Procurement from, and Servicemember Data Collection by, Companies Storing Data in a Covered Foreign Country; Prohibition on Operation or Procurement of Foreign-Made UAS; Prohibition on Procurement and Operation of Covered Robotic Systems; Prohibition on Procurement by DOD and IC of Chinese-Made Synthetic Datasets for Training AI Models; Prohibition on Transfers to the Badr Organization; Prohibition on TSP Investments; Prohibition on Use of Funds for Ukraine Security Assistance; Protecting US Farmland and Sensitive Sites from Foreign Adversaries Act; Protection of Supply Chain of Certain Drugs; Rail Infrastructure Cybersecurity Enhancement Program; Real-Time and AI-Enabled Property Records; Report and Conditions on Security Assistance to Oman; Report on Accelerating Military Posture Within Area of Responsibility of US INDOPACOM; Report on Counterintelligence Risks Associated with Real Property Transactions Near Military Installations; Report on Dependency on China for Processing Materials for DOD Supply Chains; Report on Forced Conscription of Kidnapped Ukrainian Children into Russian Armed Forces; Report on Foreign-Linked Funding of Legal and Administrative Actions Targeting US and Allied Personnel; Report on Global Automobile Theft Rings; Report on Instances of Antisemitism; Report on Involvement of Certain Foreign Actors in Antisemitic Activity in the US; Report on Military Power and Illicit Activities of Certain Drug Cartels; Report on Modernization of the Aegis Ashore Missile Defense Site at Devesselu, Romania; Report on Moldova Airspace Defense Requirements and Options; Report on PRC Space Capabilities; Report on Production of 155MM Artillery Ammunition; Report on Protection of US Defense Technology; Report on Russias Targeting of Religious Infrastructure in Ukraine; Report on Russian Active Measures in NATO Territory; Report on Russian Efforts in Sudan; Report on Russian Influence in Libya; Report on Russian Influence; Report on Russian Military Presence in Syria; Report on Security Risks Posed by Turkeys Occupation of Cyprus; Report on Taiwan Capabilities and Intelligence Support; Report on the Feasibility of Requiring Bills of Materials for Defense Acquisition; Report on the National Security Implications of Applying Nondiscriminatory Treatment to the PRC; Report on the PRC and Turkey Military and Intelligence Cooperation; Report on Turkey Aiding Hamas or Its Affiliates; Report to Congress on Energy in Moldova; Reporting on Russias Military Power and Capabilities; Reports on Cyber Operational Readiness Assessment Program; Re-Purposing Aircraft from the 309th AMARG; Requirement for Guidance and Prohibition on Use of AI of Certain AI Companies; Requirement for Memoranda of Agreement Regarding Vulnerability Disclosure and Prohibition on Procurement from IT Providers Who Can Share Cyber Vulnerabilities with Countries of Concern; Requirements Related to Certain Sanctions on Russia or Belarus; Restriction on Providing Federal Funds to Certain Entities for Public Works Projects; Restrictions on US Support for Economic Activities Involving Persons Who Benefitted from or Supported the Assad Regime; Review of Intelligence Vulnerabilities of Internet Connected Video Surveillance Equipment on Military Installations; Revocation of Security Clearances for Certain Persons; Safeguarding DOD-Funded Research; Securing Critical US Infrastructure and Mineral Supply Chains; Securing DOD Supply Chains; Securing Innovation and Research from Adversaries Act; Seizure and Forfeiture of Assets of Russian Kleptocrats; Semiconductor Controls Adjusted to Limit Exports Act; Semiconductor Supply Chain Security and Diversification Act; Sense of Congress on Commitment to the AUKUS Partnership; Sense of Congress on Domestic Production of Artillery Projectiles; Sense of Congress on International Defense Exhibitions; Sense of Congress on Nuclear Cooperation Agreements with Saudi Arabia; Sense of Congress on the Gaza Health Ministry; Sense of Congress on the Permanent and Rotational Presence of US Forces in Romania; Sense of Congress Regarding Kosovo Integration into NATO; Sense of Congress Regarding NATO's Kosovo Force; Sense of Congress with Respect to Execution of Warrants of the ICC; Space-Based Missile Defense Strategy; Standards for AI Systems; Strategic Partnership on Defense Industrial Priorities Between the US and Taiwan; Strategy for Establishing a Two-Way Transfer Mechanism for US-Ukraine UAS Expertise; Strategy for the Adoption and Integration of AI; Strategy to Defend Against Risks Posed by the Use of AI; Strategy to Restore Stability to the Western Balkans; Strengthening Continuity of the Economy Planning; Study and Report on International Security Measures on the Border Between Gaza and Egypt; Study, Strategy, and Report on DOD Reliance on Transportation Systems Incorporating Chinese-Origin Components; Taiwan-Five Eyes Cyber Defense Cooperation Initiative; Training for Ukraines Military and National Security Forces; Transatlantic Growth Enterprise Act; Tren de Aragua Border Security Threat Assessment Act; Ukraine Drone Production and Strategy; Ukrainian Military Instructors at Senior Professional Military Education Institutions; Updated Middle East IAMD Strategy; Updates to Certain Asset Lists of the DOD; Upholding the Dayton Peace Agreement Through Sanctions Act; US Counter-Robotics Strategy; US Cybersecurity Capabilities and Strategy; US Drone and Missile Defense Capabilities; US Force Posture in Korea and Europe, US Information Operations Capabilities and Strategy; US International Legal Operations Strategy; US Military Posture in Europe; US-Abraham Accords Defense Cooperation Initiative; US-Cyprus Security Cooperation; USDT Report on Financial Institutions That Support Terrorist Activity; US-European Nuclear Energy Cooperation Act; US-Greece Security Cooperation Reporting Act; US-Israel Cooperation on Space Matters; US-Israel Cooperative Research and Development; US-Israel Defense Technology Cooperation Initiative; US-Israel Security Cooperation; US-Taiwan Security Cooperation; US-Ukraine Drone Working Groups; US-Ukraine EOD Partnership; US-Ukraine Military Trauma Education, Training, Research, and Medical Readiness Partnership; and US-Ukraine Security Cooperation). S. 4784, National Defense Authorization Act for Fiscal Year 2027, (issues related to Abraham Accords Defense Cooperation Initiative; AI Functional Bill of Materials; Analysis of Threats Posed by Foreign Adversary Access to Controlled Items Within the US; Assessment of Taiwans LNG Supply Chains; Assistance to LAF for Countering Hezbollah and Other Terrorist Groups; Audit and Mitigation of Covered Cellular Modules in the DOD Systems and Infrastructure; Briefing on Military and Intelligence Presence of Cuba in the Western Hemisphere; Chinese Cellular Modules; Codification of DOD Research Security Program; Countering Cartel Hydrocarbon Smuggling; Cybersecurity Training for Veterans and Military Spouses; Derived Sourcing Requirements for AI Outputs; DETERRENCE Act; DETERRENT Act; DLA Warstopper Program; DOD Economic Defense Unit; Expansion of Permissible Uses of Ukraine Support Fund; Extension and Modification of Pacific Deterrence Initiative; Extension of Report on Military Power of the PRC; Extension, Modification, and Redesignation of Taiwan Security Cooperation Initiative; Full Accountability for Chinese Military Companies; Inspector General for Foreign Assistance; Internal Base Hardening and Staged Internal Operations; Middle East IAMD Architecture; Modifications to Requirement for Public Reporting of Chinese Military Companies Operating in the US; Multiyear Procurement Authorities; PAID OFF Act; Plan on Remediation of Certain Equipment and Computational Facilities Owned or Controlled by a Foreign Adversary; PRC EMP Capabilities; Report on the Feasibility and Advisability of Establishing a Strategic Partnership on Defense Industrial Priorities between the US and Israel; Reports on Foreign Boycotts of Israel; REVOKE Act; Safeguarding DOD-Funded Research; SECURE Minerals Act; Securing Critical Weapons Systems Supply Chains; Securing US Military Mobility Infrastructure; Securing US Transportation Systems; Stop Foreign Spyware Act; Strategic Subsea Cables Act; Taiwan Energy Security and Embargo Act; Ukraine Drone Production and Strategy; US AI Policy; US Airport Cybersecurity Enhancements; US Critical Infrastructure Resilience Against EMP Weapons; US Cybersecurity Capabilities and Strategy; US Drone and Missile Defense Capabilities; US Healthcare Cybersecurity Enhancements; US Highways Cybersecurity Enhancements; US Indo-Pacific Policy and Strategy; US Maritime Cybersecurity Enhancements; US Rail Infrastructure Cybersecurity Enhancements; US Space Capabilities and Strategy; US-India Security Cooperation; US-Israel Defense Technology Cooperation Initiative; US-Israel Security Cooperation; US-Taiwan Security Cooperation; US-Ukraine Security Cooperation; and US-Ukraine Strategic Defense Innovation Working Group). Issues Related to AUKUS Support; China-Iran-DPRK-Russia Security Cooperation and Technology Development; Chinas Military-Industrial Complex (CMIC); Chinese Military Companies; Defending Freedom of Navigation; Defense Industrial Base Modernization and Reform; DOD Diffusion of Artificial Intelligence; DODs Economic Defense Unit; Domestic and Allied Nuclear Energy Supply Chains; Domestic Production of Short-Wave Infrared Quantum Dot Materials; Hardening U.S. Military Assets and Bases; Implementation and Oversight of the NDAA (FY24 - FY26); Irans Military Strategy and Capabilities; Irans Network of Terror Proxies; Iranian Weapons Proliferation; Middle East Integrated Air and Missile Defense Architecture; Middle East Water and Food Security Working Group; Military Capability and Capacity of U.S. Allies; North Koreas Military Strategy and Capabilities; PRC Militarization and Surveillance Activities; Rebuilding U.S. Munitions Stockpile; Securing U.S. Supply Chains for Critical Weapons Systems and Munitions; U.S. Arms Control Policy; U.S. Counter-Cartel Strategy; U.S. Drone and Missile Defense Capabilities; U.S. Information Operations Capabilities and Strategy; U.S. International Legal Operations Strategy; U.S. Military Funding and Equipment; U.S. Military Operational Security Requirements; U.S. Military Posture in Europe; U.S. Military Posture in the Indo-Pacific; U.S. Military Posture in the Middle East; U.S. Nuclear Deterrence Strategy; U.S. Operations In and Against Iran; U.S. Policy on Irans Ballistic Missile and Nuclear Programs; U.S. Policy on Irans Support for Terrorism; U.S. Policy on Russias War in Ukraine; U.S.-Iraq Security Cooperation; U.S.-Israel Security Cooperation; U.S.-Lebanon Security Cooperation; U.S.-NATO Security Cooperation; U.S.-ROK Security Cooperation; U.S.-Saudi Arabia Security Cooperation; U.S.-Taiwan Security Cooperation; U.S.-Turkey Security Cooperation; U.S.-Ukraine Security Cooperation; and War Reserve Stockpiles for Allies (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOR","general_issue_code_display":"Foreign Relations","description":"H. Res. 1618, Recognizing the third anniversary of the October 7, 2023, terrorist attacks on Israel, honoring the victims and the hostages, and calling for the complete disarmament of Hamas for a durable end to the war in Gaza, all provisions. H.J. Res. 200, Providing for congressional disapproval of the proposed foreign military sale to Turkey of certain defense articles and services, all provisions. H.R. 36, MEGOBARI Act, all provisions. H.R. 3307, Eastern Mediterranean Gateway Act, all provisions. H.R. 4215, International Traffic in Arms Regulations Licensing Reform Act, all provisions. H.R. 6469, Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act, all provisions. H.R. 7380, IRAN Act, all provisions. H.R. 7622, Iran Human Rights, Internet Freedom, and Accountability Act of 2026, all provisions. H.R. 9039, Preserving Accountability for National Assets Act of 2026, all provisions. H.R. 9147, Abraham Accords Expansion Act of 2026, all provisions. H.R. 9680, Replace UNRWA with Real Humanitarian Assistance Act, all provisions. H.R. 10008, Turkey Human Rights Promotion Act of 2026, all provisions. H.R. 10183, Supporting the Rule of law, Building Institutional Justice, and Accountability (SRBIJA) Act, all provisions. H.R. 10473, Justice for Ukrainian Children Act, all provisions. H.R. 10757, To provide for a limitation on contributions to the United Nations, all provisions. S. 3360, Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act, all provisions. S. 3900, Iran Human Rights, Internet Freedom, and Accountability Act of 2026, all provisions. S. 4379, Russias War on Faith Act, all provisions. S. 4443, Eastern Mediterranean Gateway Act, all provisions. S. 4723, Eliminate PRC Organized Crime Act, all provisions. S. 5205, Turkey Human Rights Promotion Act of 2026, all provisions. S. 5611, Supporting the Rule of law, Building Institutional Justice, and Accountability (SRBIJA) Act, all provisions. H.R. 8800, National Defense Authorization Act for Fiscal Year 2027, (issues related to Abraham Accords Central Asia Expansion Act; Abraham Accords Authorities Expansion; Accountability for Terrorist Perpetrators of October 7th Act; Arms Delivery Queue Report; Arms Sales and Weapons System Transfers to NATO countries; Authorization of Activities to Counter Russia; BANNED in Latin America Act; Business in the Balkans; Captagon, Fentanyl, and International Narcotics Production and Trafficking; Certification Requirement for Major Arms Sales to Turkey; Closing Loopholes in Russia Sanctions; Countering Russias War on Faith Act; Deployment of a Financial Attache to the US Embassy in Jerusalem; Deterring Adversary Ill-Gotten Gains Act; AI OVERWATCH Act; American Space Leadership for the 21st Century Act; BIS License Administration Enhancement Act; BIS STRENGTH Act; Block the Use of Transatlantic Technology in Iranian Made Drones Act; China AI Power Report Act; Chip Security Act; Countering Chinas Control of the Caucasus; Countering Russias Forced Recruitment and Kidnapping in Africa Act; Deterring American AI Model Theft Act; Dismantle Foreign Scam Syndicates Act; Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act; Decreasing Russia Oil Profits (DROP) Act; ECRA Penalty Increase Act; ECRA Statute of Limitations Extension; Enhanced Iran Sanctions Act; Export Control Enforcement and Enhancement Act; Export Controls Enforcement Act; Foreign Adversary AI Risk Assessment and Diplomacy Act; Feasibility Review of Emerging Equipment for Digital Open Media (FREEDOM) Act; Full AI Stack Export Promotion Act; Interagency Coordination in Export Controls Act; Interagency Strategy to Disrupt and Dismantle Narcotics Production and Trafficking and Affiliated Networks Linked to the Regime of Bashar al-Assad in Syria; ITAR Licensing Reform Act; Kleptocracy Asset Recovery Rewards Program Act; Limitation on Contributions to the UN; Limitation on Transfer of Weapons to Turkey; Limitation Regarding Certain Export Controls; Multilateral Alignment of Technology Controls on Hardware (MATCH) Act; MEGOBARI Act; No US Funding for UNIFIL Act; No Official Palestine Entry (NOPE) Act; Participation of Russia in the G7; Preventing the Escalation of Armed Conflict in Europe (PEACE) Act; Peace Through Strength Act; Polisario Front Terrorist Designation Act; Preventing Rogue Equipment for Synthetic Substances (PRESS) Act; Prohibition on Delay of Arms Sales to Taiwan; Remote Access Security Act; REPO Implementation Act; Report on Allied Information Sharing to Counter Foreign Malign Influence; Report on Backlog of FMS to Taiwan; Russia-North Korea Cooperation Sanctions Act; Sanctions List Harmonization Act; Strategic Hybrid Activities Defense and Operations for the West (SHADOW) Act; STOP HATE Act; Stop Stealing Our Chips Act; Strategic Dialogue to Return Democratic Rule to Belarus; Strategic Subsea Cables Act; Streamlining Foreign Military Sales Act; Semiconductor Technology Resilience, Integrity, and Defense Enhancement (STRIDE) Act; Taiwan Allies Fund Act; Taiwan Energy Security and Anti-Embargo Act; Taiwan PLUS Act; US Arms Sales and Procurement Strategies; US Iran Sanctions Policy; US Support for the Iranian People; War Reserve Stockpiles for Allies; and XPCC Sanctions Act). S. 4784, National Defense Authorization Act for Fiscal Year 2027, (issues related to BANNED in Latin America Act; BIS License Administration Enhancement Act; BIS STRENGTH Act; China AI Power Report Act; Chip Security Act; Countering Chinas Control of the Caucuses Act; Critical Undersea Infrastructure Resilience Initiative Act; Deterring American AI Model Theft Act; Eastern Mediterranean Gateway Act; ECRA Statute of Limitations Extension Act; Eliminate PRC Organized Crime Act; FREEDOM Act; Imposition of Sanctions with Respect to Trade in Russian Origin Petroleum Products; Iran Human Rights, Internet Freedom, and Accountability Act; MATCH Act; MEGOBARI Act; No Hezbollah In Our Hemisphere Act; PORCUPINE Act; Religious Infrastructure in Ukraine; Remote Access Security Act; REPO Implementation Act; Sense of Congress on Illegal Abduction of Ukrainian Children by Russia; SHADOW Fleet Sanctions Act; Statement of Policy on Repeal of Sunset of Iran Sanctions Act of 1996; US Iran Sanctions Policy; US Legal Gold and Mining Partnership Act; US Russia Oil Waivers and Sanctions Policy; US Sanctions Authorities, Implementation, Enforcement, Resourcing, and Policy; US South Africa Bilateral Relations Review Act; and War Reserve Stockpiles for Allies). Issues related to China-Turkey Relations; Chinas Foreign Policy and Military Strategy; Chinese Activities in Latin America; Chinese Proliferation of Dual-Use Technology; Compensation for U.S. Victims of Iranian Terrorism; Congressional Oversight of U.S. Arms Sales; Congressional Oversight of U.S. Foreign Assistance; Democracy Programs in Latin America; Foreign Influence in Media; Implementation and Oversight of the Iran Nuclear Agreement Review Act; Implementation of the Atomic Energy Act; Implementation of the National Security Act of 2024; India-Middle East-Europe Economic Corridor (IMEC); Israel-Lebanon Framework Agreement; Middle East Peace Plan Implementation and Oversight; Near East Regional Democracy Program Funding; Normalization in the Middle East; Protecting International Religious Freedom; Russias Mass Abduction of Ukrainian Children; Sportswashing by U.S. Adversaries; Support for U.S. Allies at International Organizations; Turkeys Support of Terrorism; U.S. Arms Sales and Procurement Strategies; U.S. Bosnia Policy and Relations; U.S. Contributions to and Oversight of International Organizations; U.S. Energy Security Policy; U.S. Foreign Aid Policy and Reform; U.S. Global Health Policy; U.S. Policy on Chinas Human Rights Abuses and Repression; U.S. Policy on Irans Human Rights Abuses and Censorship; U.S. Policy on North Koreas Human Rights Abuses and Censorship; U.S. Serbia Policy and Relations; U.S. Support for the Iranian People; U.S. Western Balkans Strategy; U.S.-Albania Policy and Relations; U.S.-Cuba Policy and Relations; U.S.-Iran MOU and Negotiations; U.S.-Iraq Policy and Relations; U.S.-Latin America Foreign Policy and Strategy; U.S.-Mexico Policy and Relations; U.S.-Moldova Policy and Relations; U.S.-Nicaragua Policy and Relations; U.S.-Saudi 123 Agreement; U.S.-South Africa Policy and Relations; U.S.-Turkey Policy and Relations; and U.S.-Venezuela Policy and Relations (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HOM","general_issue_code_display":"Homeland Security","description":"H.R. 6105, Restricting Ex-Vetted Officials from Knowledge Exploitation (REVOKE) Act, all provisions. H.R. 6106, Conflict-free Leaving Employment and Activity Restrictions (CLEAR) Path Act, all provisions. H.R. 6107, Preventing Adversary Influence, Disinformation, and Obscured Foreign Financing (PAID OFF) Act of 2025, all provisions. H.R. 8168, Major Non-NATO Ally Terror Threat Assessment Act, all provisions. H.R. 9492, Cybersecurity Logging Enforcement and Accountability Reporting Act, all provisions. H.R. 9834, No Racketeers on our Shores Act, all provisions. S. 2132, CLEAR Path Act, all provisions. S. 3050, Preventing Adversary Influence, Disinformation, and Obscured Foreign Financing (PAID OFF) Act of 2025, all provisions. S. 3181, REVOKE Act, all provisions. S. 4697, Stop TNR Act of 2026, all provisions. S. 4699, Guaranteeing Universal Access to Cybersecurity Act, all provisions.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"H.R. 2683, Remote Access Security Act, all provisions. H.R. 7625, Marine Transportation System Cybersecurity Budget and Evaluation Report (MTS CYBER) Act of 2026, all provisions. H.R. 8283, Deterring American AI Model Theft Act of 2026, all provisions. H.R. 8730, Connected Vehicle Security Act of 2026, all provisions. H.R. 9102, Biotech Investment National Security Act (BINSA), all provisions. H.R. 9129, Guarding the U.S. Against Adversarial Robotics Dominance (GUARD) Act of 2026, all provisions. H.R. 9592, American Space Leadership for the 21st Century Act, all provisions. H.R. 10670, China FIREWALL Act, all provisions. H.R. 10695, United States Submarine Cable Security Policy Act of 2026, all provisions. S. 3519, Remote Access Security Act, all provisions. S. 4429, Connected Vehicle Security Act of 2026, all provisions. S. 4939, Countering CCP Act, all provisions. S. 5316, Biotech Investment National Security Act (BINSA), all provisions. Issues Related to Adversarial Distillation of American AI Models; Chinese Biotech Industry and Dual-Use Threats; Chinese EV Manufacturing; Chinese Robotics Capabilities and Strategy; Cybersecurity Capabilities of U.S. Allies; Development of Internet Access Technologies; Information Technology Devices from Foreign Adversary Controlled Companies; Light Detection and Ranging Sensor Technology; National Guard Role in Cyber Incident Response; National Security Capabilities of Advanced AI Systems; NATO Cybersecurity Capabilities and Strategy; Securing Critical U.S. Infrastructure and Mineral Supply Chains; Securing U.S. Defense Technology; Securing U.S. Military Mobility Infrastructure; Securing U.S. Transportation Systems; TikTok Operations and Safeguards; U.S. Adversarial Use of AI and Quantum Technology; U.S. AI Chip Security; U.S. Airport Cybersecurity Enhancements; U.S. Artificial Intelligence Policy and Regulation; U.S. Cybersecurity Capabilities and Strategy; U.S. Drone Production and Market Security; U.S. Emerging Technology Capabilities, Development, and Strategy; U.S. Healthcare Cybersecurity Enhancements; U.S. Highways Cybersecurity Enhancements; U.S. Maritime Cybersecurity Enhancements; U.S. Open Technology Fund; U.S. Rail Infrastructure Cybersecurity Enhancements; U.S. Space Capabilities and Strategy; and U.S. Technology-Security Strategy (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"H.R. 1048, Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act, all provisions. H.R. 8901, Securing Innovation and Research from Adversaries Act, all provisions. H.R.1049, Transparency in Reporting of Adversarial Contributions to Education (TRACE) Act, all provisions. S. 1296, Defending Education Transparency and Ending Rogue Regimes Engaging in Nefarious Transactions (DETERRENT) Act, all provisions. S. 2509, Transparency in Reporting of Adversarial Contributions to Education (TRACE) Act, all provisions. Issues related to Foreign Gift Compliance Transparency; Foreign Influence and Investments in Nonprofit Sector; Foreign Influence and Investments in U.S. Higher and Elementary Education; and Securing American Funding and Expertise from Adversarial Research Exploitation (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to Illegal Transshipment of Goods (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"INT","general_issue_code_display":"Intelligence","description":"Issues related to Foreign Malign Influence Operations (no bill).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":141587,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW REID","nickname":null,"middle_name":"WITTE","last_name":"ZWEIG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152508,"prefix":null,"prefix_display":null,"first_name":"DANIEL","nickname":null,"middle_name":null,"last_name":"VAYNSHTEYN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71983,"prefix":null,"prefix_display":null,"first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"STAPLETON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152507,"prefix":null,"prefix_display":null,"first_name":"ALEXANDRIA","nickname":null,"middle_name":null,"last_name":"PAOLOZZI MOORE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146703,"prefix":"mr","prefix_display":"MR.","first_name":"CONNOR","nickname":null,"middle_name":"RUSSELL","last_name":"PFEIFFER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151813,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"JUTCOVICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/de0425b3-58b7-476d-9a4e-bfb6953c7984/","filing_uuid":"de0425b3-58b7-476d-9a4e-bfb6953c7984","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/de0425b3-58b7-476d-9a4e-bfb6953c7984/print/","filing_document_content_type":"text/html","income":null,"expenses":"190000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Amy Shank","dt_posted":"2026-10-20T12:07:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"9901 S. Wilcrest Dr","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Houston","registrant_state":"TX","registrant_zip":"77099","registrant":{"id":401103386,"url":"https://lda.gov/api/v1/registrants/401103386/","house_registrant_id":null,"name":"PROFESSIONAL COMPOUNDING CENTERS OF AMERICA","description":"Membership organization providing resources to independent compounding pharmacies","address_1":"9901 S. Wilcrest Dr","address_2":null,"address_3":null,"address_4":null,"city":"Houston","state":"TX","state_display":"Texas","zip":"77099","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMY SHANK","contact_telephone":"+1 202-412-0412","dt_updated":"2026-07-24T14:07:59.280567-04:00"},"client":{"id":198794,"url":"https://lda.gov/api/v1/clients/198794/","client_id":12,"name":"PROFESSIONAL COMPOUNDING CENTERS OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-07-21"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154528,"prefix":null,"prefix_display":null,"first_name":"CLAIRE","nickname":null,"middle_name":null,"last_name":"CASEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154528,"prefix":null,"prefix_display":null,"first_name":"CLAIRE","nickname":null,"middle_name":null,"last_name":"CASEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":60863,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"SHANK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154528,"prefix":null,"prefix_display":null,"first_name":"CLAIRE","nickname":null,"middle_name":null,"last_name":"CASEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/e1e81663-8dc7-4a88-bedb-b1e005aba204/","filing_uuid":"e1e81663-8dc7-4a88-bedb-b1e005aba204","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/e1e81663-8dc7-4a88-bedb-b1e005aba204/print/","filing_document_content_type":"text/html","income":"20000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Stephen P. Roberts, Attorney & Agent for Filer","dt_posted":"2026-10-20T12:28:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"750 Main Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Cambridge","registrant_state":"MA","registrant_zip":"02139","registrant":{"id":401103747,"url":"https://lda.gov/api/v1/registrants/401103747/","house_registrant_id":null,"name":"SACHEM STRATEGIES","description":"Lobbying firm","address_1":"750 Main Street","address_2":null,"address_3":null,"address_4":null,"city":"Cambridge","state":"MA","state_display":"Massachusetts","zip":"02139","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NATHANIEL WALTON","contact_telephone":"+1 617-780-2252","dt_updated":"2026-07-30T17:42:40.417693-04:00"},"client":{"id":69985,"url":"https://lda.gov/api/v1/clients/69985/","client_id":69985,"name":"STRAND THERAPEUTICS","general_description":"mRNA therapeutics company","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-10-06"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to biomanufacturing policy (H.R. 9102 / S. 5316 Biotech Investment National Security Act).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62270,"prefix":null,"prefix_display":null,"first_name":"NATHANIEL","nickname":null,"middle_name":null,"last_name":"WALTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7b7372e1-551f-4eac-afa5-105a6670c2fe/","filing_uuid":"7b7372e1-551f-4eac-afa5-105a6670c2fe","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/7b7372e1-551f-4eac-afa5-105a6670c2fe/print/","filing_document_content_type":"text/html","income":null,"expenses":"1530000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brent Fisk","dt_posted":"2026-10-20T16:45:00-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 F STREET, NW, #1000","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16293,"url":"https://lda.gov/api/v1/registrants/16293/","house_registrant_id":31461,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","description":"PHARMACEUTICALS","address_1":"1201 F STREET, NW, #480","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRENT FISK","contact_telephone":"+1 703-501-8920","dt_updated":"2026-10-05T10:48:35.722200-04:00"},"client":{"id":121722,"url":"https://lda.gov/api/v1/clients/121722/","client_id":12,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Peptides/counterfeiting policy issues Controlled substances policy issues Generics/devices policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B Rebate Model Pilot Program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 10628: Biosimilars Access and Affordability Act S. 5571: Biosimilars Access and Affordability Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":155671,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"MCCONE","suffix":null,"suffix_display":null},"covered_position":"Rep. Jan Schakowsky, Intern, June 2014-Aug 2014, Rep. Joe Crowley, Intern, Jan 2016-April 2016, Rep. Chuck Schumer, Intern, April 2016-July 2016, Rep. Raja Krishnamoorthi, Sept 2017-May 2018, Rep. Mark Pocan, Scheduler, May 2018-May 2020","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/afab4741-599f-4aea-ae8f-597ba4797e76/","filing_uuid":"afab4741-599f-4aea-ae8f-597ba4797e76","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/afab4741-599f-4aea-ae8f-597ba4797e76/print/","filing_document_content_type":"text/html","income":null,"expenses":"7040000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Paul J. Larsen","dt_posted":"2026-10-20T16:51:50-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"670 Maine Avenue, SW","registrant_address_2":"Suite 1000","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":31350,"url":"https://lda.gov/api/v1/registrants/31350/","house_registrant_id":30654,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","description":null,"address_1":"670 Maine Avenue, SW","address_2":"Suite 1000","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL J. LARSEN","contact_telephone":"+1 202-835-3400","dt_updated":"2026-07-30T11:08:37.463508-04:00"},"client":{"id":138226,"url":"https://lda.gov/api/v1/clients/138226/","client_id":12,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 6500: Continuing Appropriations and Extensions Act, 2027 (Public Law 119-103) Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act S. 3794: SAFE Drugs Act of 2026 S. 4189: INSULIN Act of 2026 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5244: SUSTAIN 340B Act H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 946: ORPHAN Cures Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6509: SAFE Drugs Act of 2025 H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Peptides/counterfeiting policy issues Controlled substances policy issues Generics/devices policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B Rebate Model Pilot Program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62437,"prefix":null,"prefix_display":null,"first_name":"SYLVIA","nickname":null,"middle_name":null,"last_name":"YU","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4299: Protecting Patient Access to Cancer and Complex Therapies Act H.R. 10628: Biosimilars Access and Affordability Act S. 5571: Biosimilars Access and Affordability Act Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62437,"prefix":null,"prefix_display":null,"first_name":"SYLVIA","nickname":null,"middle_name":null,"last_name":"YU","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 3452: Biological Intellectual Property Protection Act of 2025 S. 5043: Secure Drug Supply Chain Act of 2026 S. 5265: USTRx Act S. 5316: Biotech Investment National Security Act (BINSA) H.R. 4780: USTRx Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}